Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

Postherpetic Neuralgia Clinical Trial

Official title:

A DOUBLE BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP EVALUATION OF CIVAMIDE (ZUCAPSAICIN) 0.01% AND VEHICLE NASAL SPRAYS IN THE TREATMENT OF POSTHERPETIC NEURALGIA OF THE TRIGEMINAL NERVE

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01886313
• Other study ID #: WL-1001-07-01
• Status: Terminated
• Phase: Phase 2
• First received: June 20, 2013
• Last updated: December 7, 2015
• Start date: March 2014
• Est. completion date: April 2015

Study information

• Verified date: December 2015
• Source: Winston Laboratories
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Herpes zoster (commonly referred to as "shingles") results from the reactivation of the varicella-zoster virus acquired during a primary infection, usually chickenpox. The virus lays dormant in the cells of the nerves until activated. Once activated, patients develop a characteristic red blistering rash which crusts and heals in 2 - 4 weeks. Postherpetic neuralgia (PHN), the term for pain persisting after the herpes zoster (HZ) eruption heals, is the most common and most feared complication of herpes zoster infection. The drug, Civamide is thought to desensitize the nerves and decrease the pain of PHN. This is the pharmacologic rationale for its use in the nose in postherpetic neuralgia of the trigeminal nerve, a nerve that is in the nose and transmits pain from the face. The objective of this study is to evaluate the safety and efficacy of intranasally administered Civamide (0.01%) for the treatment of moderate to severe daily pain associated with postherpetic neuralgia of the trigeminal nerve. Neuropathic pain must have persisted for ≥ 12 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: April 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subject voluntarily agrees to participate in this study and signs an IRB-approved informed consent prior to performing any of the screening procedures.

2. Subject is in generally good health other than a history of postherpetic neuralgia, determined by pre-study medical evaluation (medical history, physical examination including examination of the treatment area, and vital signs) and without evidence of underlying unstable acute or chronic systemic disease, e.g. diabetes.

3. Subject has experienced on average, moderate to severe chronic postherpetic neuralgia restricted to the distribution of the affected trigeminal nerve or its divisions for at least 12 months after healing of a herpes zoster skin rash.

4. Subject has Average Daily Pain Score of 4 or higher on the 11-point numeric rating scale during the 7-Day Baseline Period.

5. Males or females between 21 to 80 years of age, inclusive.

6. Non-pregnant, non-lactating females of childbearing potential who agree to use medically acceptable forms of birth control (abstinence, hormonal contraceptives, diaphragm with spermicide, condom with spermicide, or intrauterine device) throughout the study or females of non-childbearing potential (surgically sterile [hysterectomy or bilateral tubal ligation] or post-menopausal = 1 year). A negative urine pregnancy test must be confirmed at screening for all female subjects who are not surgically sterile.

7. The subject agrees not to begin any new concomitant medications during their participation in study.

Exclusion Criteria:

1. Subject has a history of frequent headache or other painful conditions, other than that associated with PHN, within the past 30 days that has required or is expected to require the additional use (beyond stable daily doses) of prescription or over the counter pain relief medication, such as non-steroidal anti-inflammatory agents, including COX-2 inhibitors, systemic opiates or derivatives, or acetaminophen more than 2 times per week during the study. Concurrent medications and stable dose requirements are listed in Table 3.

2. Clinical, historical or previous laboratory evidence of significant cardiovascular, renal, gastrointestinal, pulmonary, hepatic, endocrine, neurological, psychological, or other systemic disease that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk to the subject.

3. Presence of a significant nasal disorder.

4. Subject is immunocompromised (e.g. AIDS, significant oncologic disease, immunocompromising medications, etc.).

5. Subject received neurolytic or neurosurgical therapy for this or previous episodes of postherpetic neuralgia.

6. Use of any restricted medication within the given time period prior to the Baseline Period and throughout the study (see Table 1).

7. Subject has a history of alcohol and/or drug abuse within the past year.

8. Subject has previously participated in a Civamide study.

9. Subject has participated in another investigational study or taken another investigational drug within the past 30 days.

10. Subject has difficulty distinguishing his/her PHN head pain from other types of head pain, such as tension-type headaches.

11. Known hypersensitivity to or contraindication to the use of Civamide (zucapsaicin), capsaicin (Zuacta®, Zostrix®, Zostrix-HP®, Axsain®, or related products) or to any excipient of the clinical formulation.

12. Initiation of a medication, discontinuation of a medication or change in regimen of existing medication(s) or therapies less than the required period of stable dosing prior to entering the Baseline Period. (See table 2.)

13. If, for any other reason, the subject is not deemed to be suitable by the Investigator, they should not be enrolled.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neuralgia
• Neuralgia, Postherpetic
• Postherpetic Neuralgia

Intervention

Drug:
• Civamide Nasal Spray

• Placebo

Locations

Country	Name	City	State
United States	Michigan Head Pain and Neurological Institute	Ann Arbor	Michigan
United States	Furture Search Trials of Neurology, LP	Austin	Texas
United States	Sun Rise Medical	Lauderdale Lakes	Florida
United States	California Medical Clinic for Headache	Santa Monica	California
United States	Meridien Research	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Winston Laboratories

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Average Daily Sleep Score	Changes in the secondary efficacy variables from the Baseline Period to the last week of the Treatment Period and other weeks in the study in Average Daily Sleep Score (11-point NRS)	Weeks 1 to 6	No
Other	Skin Sensitivity	Changes in the secondary efficacy variables from the Baseline Period to the last week of the Treatment Period and other weeks in the study for Skin Sensitivity Assessment (11-point NRS)	Weeks 1 to 6	No
Other	Subject Global Impression of Change	Changes in the secondary efficacy variables from the Baseline Period to the last week of the Treatment Period and other weeks in the study in Subject Global Impression of Change (7-point Likert scale)	Weeks 1 to 6	No
Other	Investigator Global Impression of Change	Changes in the secondary efficacy variables from the Baseline Period to the last week of the Treatment Period and other weeks in the study in Investigator Global Impression of Change (7-point Likert scale)	Weeks 1 to 6	No
Other	Requirement for Acute Medication	Changes in the secondary efficacy variables from the Baseline Period to the last week of the Treatment Period and other weeks in the study in Requirement for Acute Medication	Weeks 1 to 6	No
Primary	Average Daily Pain Score	Change in Average Daily Pain Score (11-point Numeric Rating Scale [NRS]) from the Baseline Period to the Average Daily Pain Score of the last week (Week 6) of the Treatment Period.	6 weeks	No
Secondary	Average Daily Pain Score	Change in Average Daily Pain Score from the Baseline Period to the Average Daily Pain Score of each of weeks 1 - 5 of the study.	Weeks 1 to 5	No